Evidence map›Paper›PMID 22426779›Full record

ArticleMolecular and cellular biochemistry2012

Characterization of the high-affinity uptake of fructose-1,6-bisphosphate by cardiac myocytes.

Thomas J Wheeler, Sufan Chien

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Thomas J WheelerDepartment of Biochemistry and Molecular Biology, University of Louisville School of Medicine, Louisville, KY, USA.
Sufan Chien
University of Louisville · US

Funding

ENHANCED GLYCOLYSIS FOR HYPOTHERMIC HEART PRESERVATIONR01HL064186 · NHLBI · UNIVERSITY OF LOUISVILLE · PI CHIEN, SUFAN · 2000 to 2003
$1.5M
NHLBI NIH HHS HL64186
6 · The paper itself

Abstract

Previously, we reported that fructose-1,6-bisphosphate (FBP) was taken up by rat cardiac myocytes by two processes: a component that was saturable at micromolar levels and a nonsaturable component that dominated at millimolar levels. Here, we continued to characterize the saturable high-affinity component, with the aim of identifying the physiological substrate and role for this activity. ATP, ADP, and AMP inhibited the uptake of FBP with apparent affinities of 0.2-0.5 mM. Fumarate and succinate were very weak inhibitors. Several phosphorylated sugars (ribulose-1,5-phosphate, fructose-1-phosphate, ribose-5-phosphate, and inositol-2-phosphate) inhibited FBP uptake with apparent affinities of 40-500 μM. As in our previous study, no tested compound appeared to bind as well as FBP. The data suggest that the best ligands have two phosphoryl groups separated by at least 8 Å. The rates of FBP uptake were measured from 3° to 37°. The calculated activation energy was 15-50 kJ/mol, similar to other membrane transport processes. Uptake of FBP was tested in several types of cells other than cardiac myocytes, and compared to the uptake of 2-deoxyglucose and L: -glucose. While FBP uptake in excess of that of L: -glucose was observed in some cells, in no case was the uptake as high as in cardiac myocytes. The physiological substrate and role for the high-affinity FBP uptake activity remain unknown.

Indexed as

Cell Membrane PermeabilityAdenine NucleotidesAnimalsCells, CulturedFructosediphosphatesHumansMaleMembrane Transport ProteinsMiceMyocytes, CardiacRatsRats, Sprague-DawleySugar PhosphatesThermodynamicsAdenine Nucleotidesfructose-1,6-diphosphateFructosediphosphatesMembrane Transport ProteinsSugar Phosphates

Identifiers

PMID22426779
OpenAlexW2026071543

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.